Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized phase II study of FOLFIRI + bevacizumab with or without bevacizumab maintenance during chemotherapy-free intervals in metastatic colorectal cancer
2008-007928-25Phase 2Active
- Sponsor
- Fédération Francophone de Cancérologie Digestive
- Start
- Mar 2009
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of bevacizumab, irinotecan, folinic acid and fluorouracil in colorectal cancer (CRC) and colorectal adenocarcinoma (2 arms), sponsored by Fédération Francophone de Cancérologie Digestive. Started Mar 2009; status: active.
02
Drugs
bevacizumabirinotecanfolinic acidfluorouracil
03
Conditions
colorectal cancer (CRC)colorectal adenocarcinoma
Beyond the preview
Go deeper on 2008-007928-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-007928-25.